Effects of mexiletine, propafenone and flecainide on signal-averaged electrocardiogram. 1992

F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
Istituto Ricerche Cardiovascolari, Cardiologia Ospedale, L. Sacco, Centro Fidia, Università Milano, Italy.

The effects of mexiletine, propafenone and flecainide on the parameters of signal-averaged electrocardiogram in 40 subjects with symptomatic and repetitive ventricular arrhythmias were studied. Mexiletine (n = 16) suppressed ventricular arrhythmias in 10 patients and did not produce any significant changes in filtered QRS duration (fQRS), root mean square voltage of the final 40 ms of filtered QRS (RMS40) or low amplitude terminal component duration (LAS40). Acute (n = 8, 450 mg) and chronic (n = 16, 600-1200 mg.day-1) administration of propafenone determined a significant increase in fQRS (from 123 +/- 2.2 to 139 +/- 3 ms) and a reduction in RMS40 (from 54 +/- 8.8 to 34 +/- 6.7 microV); as a consequence the incidence of ventricular late potentials rose from 43 to 62%. The observed effects were independent of anti-arrhythmic efficacy, which was 86% for this drug. Acute (n = 8, 200 mg) and chronic (n = 13, 200-300 mg.day-1) administration of flecainide was associated with a marked prolongation in fQRS (from 123 +/- 2.8 to 138 +/- 4.1 ms) and a reduction in RMS40 (from 69 +/- 11.5 to 47 +/- 11 microV); thus determining an increase in the incidence of ventricular late potentials from 29 to 48%. Changes in signal-averaged electrocardiogram were not related to drug efficacy, which was 81%. These data indicate that 1c anti-arrhythmic drugs consistently modified the parameters of signal-averaged electrocardiogram; the observed changes might reflect an inhomogeneous slowing of intramyocardial impulse propagation.

UI MeSH Term Description Entries
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011405 Propafenone An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Apo-Propafenone,Arythmol,Baxarytmon,Cuxafenon,Fenoprain,Jutanorm,Nistaken,Norfenon,Pintoform,Prolecofen,Propafenon AL,Propafenon Hexal,Propafenon Minden,Propafenone Hydrochloride,Propafenone Hydrochloride, (R)-Isomer,Propafenone Hydrochloride, (S)-Isomer,Propafenone, (+-)-Isomer,Propafenone, (R)-Isomer,Propafenone, (S)-Isomer,Propamerck,Rythmol,Rytmo-Puren,Rytmogenat,Rytmonorm,SA-79,Hydrochloride, Propafenone,SA 79,SA79
D005260 Female Females
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
February 1996, Pacing and clinical electrophysiology : PACE,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
April 2003, Nihon rinsho. Japanese journal of clinical medicine,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
March 1997, Nihon rinsho. Japanese journal of clinical medicine,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
November 1994, Pacing and clinical electrophysiology : PACE,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
September 1990, The American journal of cardiology,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
December 1982, Annales de cardiologie et d'angeiologie,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
March 1990, American heart journal,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
January 1996, The American journal of cardiology,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
January 2018, Journal of electrocardiology,
F Lombardi, and M L Finocchiaro, and L Dalla Vecchia, and R Rech, and A Castelli, and J Pastine, and E Cappiello
December 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!